Market Alert: Ceasefire Hopes Between Israel and Iran Falter, Renewing Market Volatility
Vitasora Health Limited (ASX: VHL), formerly Respiri, is a digital healthcare innovator offering a connected care management platform that integrates various medical devices with its proprietary remote patient monitoring (RPM) software. Targeting the U.S. market, Vitasora supports chronic care management by reducing re-hospitalisations and improving medication adherence. The company’s strategic growth is anchored by value-based partnerships like its expanded contract with TPAC, now covering 15,000 Medicare lives, with potential reach to over 1.2 million patients through upcoming deals. Vitasora projects an ARR of US$18 million by H2 CY26, up from the current US$5.5 million. Backed by proven clinical outcomes (e.g., 56% fewer re-hospitalisations), a scalable model, and seasoned leadership, it raised AU$11 million in July 2025 to fund U.S. expansion. Its unique turnkey service simplifies clinical integration, making it a competitive force in the US$30 billion RPM market expected by 2030.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Jul 02, 2025
Jul 02, 2025
Jul 02, 2025
Jul 02, 2025
Jul 02, 2025
Jul 02, 2025
Jul 02, 2025
Jul 02, 2025
Jul 01, 2025
Jul 01, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.